Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world study
Disitamab vedotin联合程序性死亡受体1抑制剂治疗既往接受过治疗的HER2过表达晚期胃癌:一项多中心回顾性真实世界研究
期刊:
影响因子:
doi:10.1080/07853890.2025.2569994
Yan, Xiao; Xie, Zhong; Ouyang, Kaobin; Lai, Mingyu; Yang, Li; Huang, Tianying; Li, Fengping; Liang, Huayuan; Huang, Kaihua; Li, Zhiwei; Xie, Qing; Zhong, Rou; Zhang, Huimin; Lai, Min; Qiu, Miaozhen; Zhao, Liying